Download PDF
Laryngorhinootologie 2022; 101(09): 736-740
DOI: 10.1055/a-1830-8298
Originalarbeit

Pembrolizumab und Cetuximab als therapeutische Optionen für adenoidzystische Karzinome des Kopf-Hals-Bereiches

Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck
Ioannis Michaelides∗
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
2   Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland
,
Sandra Fest∗
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
,
Michael Berszin
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
,
Susanne Wiegand
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
,
Christopher Bohr
2   Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland
,
Julian Künzel
2   Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland
,
Andreas Dietz
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
,
Markus Pirlich‡
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
,
Gunnar Wichmann‡
1   Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Schlüsselwörter

Adenoid-zystisches Karzinom - Kopf-Hals-Tumore - ex vivo - FLAVINO-Assay - Chemoresponse-Test - Pembrolizumab - Cetuximab - Immun-Checkpoint-Blockade - PD-1/PD-L1 Signalweg

Keywords

Adenoid-cystic carcinoma (ACC) - head and neck cancer - FLAVINO assay - chemoresponse test - pembrolizumab - cetuximab


Publication History

Received: 14 October 2021

Accepted after revision: 14 April 2022

Article published online:
16 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bilroth T. Germany: G Riemer; 1856. The Cylindroma Studies on the development of the blood vessels along with observations from the Royal University Surgical Clinic Berlin.55–69.
    PubMed
  • 2 Bubendorf L, Feichter GE, Obermann EC. et al. Pathologie – Zytopathologie.
    PubMed
  • 3 Böcker W, Denk H, Heitz PU. et al. Lehrbuch Pathologie. Elsevier Health Sciences. 2019
    PubMedSearch in Google Scholar
  • 4 Martinez-Rodriguez N, Leco-Berrocal I, Rubio-Alonso L. et al. Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: a meta-analytic study. Med Oral Patol Oral Cir Bucal 2011; 16 (07) e884-e889
    CrossrefPubMedSearch in Google Scholar
  • 5 Miglianico L, Eschwege F, Marandas P. et al. Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13 (05) 673-678
    CrossrefPubMedSearch in Google Scholar
  • 6 Hosni A, Huang SH, Goldstein D. et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol 2016; 54: 75-80
    CrossrefPubMedSearch in Google Scholar
  • 7 Licitra L, Cavina R, Grandi C. et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 07 (06) 640-642
    CrossrefPubMedSearch in Google Scholar
  • 8 Hill M, Constenla D, Ahern R. et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997; 33 (04) 275-278
    CrossrefPubMedSearch in Google Scholar
  • 9 Suzuki S, Dobashi Y, Minato H. et al. EGFR and HER2–Akt–mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Archiv 2012; 461 (03) 271-282
    CrossrefPubMedSearch in Google Scholar
  • 10 Sridharan V, Gjini E, Liao X. et al. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res 2016; 04 (08) 679-687
    CrossrefPubMedSearch in Google Scholar
  • 11 Hitre E, Budai B, Takacsi-Nagy Z. et al. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 2013; 109 (05) 1117-1122
    CrossrefPubMedSearch in Google Scholar
  • 12 Mahmood U, Bang A, Chen YH. et al. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys 2020;
    CrossrefPubMedSearch in Google Scholar
  • 13 Moskaluk CA. Adenoid cystic carcinoma: clinical and molecular features. Head Neck Pathol 2013; 07 (01) 17-22
    CrossrefPubMedSearch in Google Scholar
  • 14 Azumi N, Battifora H. The cellular composition of adenoid cystic carcinoma. An immunohistochemical study 1987; 60 (07) 1589-1598
    CrossrefPubMedSearch in Google Scholar
  • 15 Caselitz J, Schulze I, Seifert G. Adenoid cystic carcinoma of the salivary glands: an immunohistochemical study. J Oral Pathol 1986; 15 (06) 308-318
    CrossrefPubMedSearch in Google Scholar
  • 16 Bell D, Roberts D, Kies M. et al. Cell type-dependent biomarker expression in adenoid cystic carcinoma. Cancer 2010; 116 (24) 5749-5756
    CrossrefPubMedSearch in Google Scholar
  • 17 Da Cruz Perez DE, De Abreu Alves F, Nobuko Nishimoto I. et al. Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncology 2006; 42 (02) 139-146
    CrossrefPubMedSearch in Google Scholar
  • 18 Dillon PM, Chakraborty S, Moskaluk CA. et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head & Neck 2016; 38 (04) 620-627
    CrossrefPubMedSearch in Google Scholar
  • 19 Amit M, Binenbaum Y, Trejo-Leider L. et al. International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head & Neck 2015; 37 (07) 1038-1045
    CrossrefPubMedSearch in Google Scholar
  • 20 Dietz A, Boehm A, Horn IS. et al. Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 2010; 267 (04) 483-494
    CrossrefPubMedSearch in Google Scholar
  • 21 Chae YK, Chung SY, Davis AA. et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget 2015; 06 (35) 37117-37134
    CrossrefPubMedSearch in Google Scholar
  • 22 Jagielska B, Sarnowska E, Sarnowski T. et al. Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck. Oncology in Clinical Practice 2020; 16 (01) 1-8
    CrossrefPubMedSearch in Google Scholar
  • 23 Papaspyrou G, Hoch S, Rinaldo A. et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 33 (06) 905-911
    CrossrefPubMedSearch in Google Scholar
  • 24 Lagha A, Chraiet N, Ayadi M. et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head & Neck Oncology 2012; 04 (01) 19
    CrossrefPubMedSearch in Google Scholar
  • 25 Subramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Irish Journal of Medical Science (1971 -) 2015; 184 (03) 583-590
    CrossrefPubMedSearch in Google Scholar
  • 26 Gessner K, Wichmann G, Boehm A. et al. Therapeutic options for treatment of Merkel cell carcinoma. Eur Arch Otorhinolaryngol 2011; 268 (03) 443-448
    CrossrefPubMedSearch in Google Scholar
  • 27 Liu NN, Zhang SL, Chen W. The cross-contaminated cell lines of adenoid cystic carcinoma: A crucial concern. Translational Surgery 2017; 02 (01) 10-13
    CrossrefPubMedSearch in Google Scholar